Aptabio Therapeutics Stock Annual Yield
| 293780 Stock | 6,630 570.00 7.92% |
AptaBio Therapeutics fundamentals help investors to digest information that contributes to AptaBio Therapeutics' financial success or failures. It also enables traders to predict the movement of AptaBio Stock. The fundamental analysis module provides a way to measure AptaBio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AptaBio Therapeutics stock.
AptaBio |
AptaBio Therapeutics Company Annual Yield Analysis
AptaBio Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, AptaBio Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Biotechnology & Medical Research (which currently averages 0.0) industry. This indicator is about the same for all Republic of Korea stocks average (which is currently at 0.0).
AptaBio Annual Yield Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AptaBio Therapeutics' direct or indirect competition against its Annual Yield to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AptaBio Therapeutics could also be used in its relative valuation, which is a method of valuing AptaBio Therapeutics by comparing valuation metrics of similar companies.AptaBio Therapeutics is currently under evaluation in annual yield category among its peers.
AptaBio Fundamentals
| Return On Equity | -17.47 | |||
| Return On Asset | -0.0568 | |||
| Operating Margin | (17.13) % | |||
| Current Valuation | 794.49 B | |||
| Shares Outstanding | 10.88 M | |||
| Shares Owned By Insiders | 34.04 % | |||
| Shares Owned By Institutions | 3.46 % | |||
| Price To Sales | 926.14 X | |||
| Revenue | 223.68 M | |||
| Gross Profit | 336.97 M | |||
| EBITDA | (6.58 B) | |||
| Net Income | (10.69 B) | |||
| Cash And Equivalents | 6.57 B | |||
| Total Debt | 46.77 M | |||
| Cash Flow From Operations | (8.9 B) | |||
| Beta | 2.39 | |||
| Market Capitalization | 111.21 B | |||
| Total Asset | 64.91 B | |||
| Net Asset | 64.91 B |
About AptaBio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AptaBio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AptaBio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AptaBio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in AptaBio Stock
AptaBio Therapeutics financial ratios help investors to determine whether AptaBio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AptaBio with respect to the benefits of owning AptaBio Therapeutics security.